Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma
Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy. Case presentation A 65‐year‐old man was diagnosed with left renal cell carcinoma of cT2aN0M1 with l...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-11-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12220 |
| _version_ | 1818382965086879744 |
|---|---|
| author | Hiroki Hagimoto Soki Kashima Kazuki Doi Shintaro Nakayama Takanori Sano Satoshi Imai Tomihiko Yasufuku Mototsugu Muramaki Yuji Yamada |
| author_facet | Hiroki Hagimoto Soki Kashima Kazuki Doi Shintaro Nakayama Takanori Sano Satoshi Imai Tomihiko Yasufuku Mototsugu Muramaki Yuji Yamada |
| author_sort | Hiroki Hagimoto |
| collection | DOAJ |
| description | Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy. Case presentation A 65‐year‐old man was diagnosed with left renal cell carcinoma of cT2aN0M1 with lung metastasis. The patient underwent nephrectomy and sequential therapy with interferon‐α and angiogenesis inhibitors. Lung metastasis decreased by angiogenesis inhibitors, but new right adrenal gland metastasis appeared. Nivolumab as the fifth systemic therapy remarkably shrank the metastasis. After discontinuing nivolumab therapy, the metastasis continued to shrink. The patient underwent adrenalectomy, and pathological analysis revealed no remnant cancer cells in the specimen, confirming a pathological complete response. Twenty months postoperatively, he remains in good health without recurrence. Conclusion We report a rare case with renal cell carcinoma of a pathological complete response by nivolumab after angiogenesis inhibitors. |
| first_indexed | 2024-12-14T02:58:51Z |
| format | Article |
| id | doaj.art-fb56cc9cf4c1481ba8890b0ecbd0898a |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-12-14T02:58:51Z |
| publishDate | 2020-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-fb56cc9cf4c1481ba8890b0ecbd0898a2022-12-21T23:19:34ZengWileyIJU Case Reports2577-171X2020-11-013628729010.1002/iju5.12220Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinomaHiroki Hagimoto0Soki Kashima1Kazuki Doi2Shintaro Nakayama3Takanori Sano4Satoshi Imai5Tomihiko Yasufuku6Mototsugu Muramaki7Yuji Yamada8Department of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto KyotoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanDepartment of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki HyogoJapanIntroduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy. Case presentation A 65‐year‐old man was diagnosed with left renal cell carcinoma of cT2aN0M1 with lung metastasis. The patient underwent nephrectomy and sequential therapy with interferon‐α and angiogenesis inhibitors. Lung metastasis decreased by angiogenesis inhibitors, but new right adrenal gland metastasis appeared. Nivolumab as the fifth systemic therapy remarkably shrank the metastasis. After discontinuing nivolumab therapy, the metastasis continued to shrink. The patient underwent adrenalectomy, and pathological analysis revealed no remnant cancer cells in the specimen, confirming a pathological complete response. Twenty months postoperatively, he remains in good health without recurrence. Conclusion We report a rare case with renal cell carcinoma of a pathological complete response by nivolumab after angiogenesis inhibitors.https://doi.org/10.1002/iju5.12220metastasectomynivolumabrenal cell cancer |
| spellingShingle | Hiroki Hagimoto Soki Kashima Kazuki Doi Shintaro Nakayama Takanori Sano Satoshi Imai Tomihiko Yasufuku Mototsugu Muramaki Yuji Yamada Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma IJU Case Reports metastasectomy nivolumab renal cell cancer |
| title | Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| title_full | Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| title_fullStr | Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| title_full_unstemmed | Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| title_short | Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| title_sort | pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma |
| topic | metastasectomy nivolumab renal cell cancer |
| url | https://doi.org/10.1002/iju5.12220 |
| work_keys_str_mv | AT hirokihagimoto pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT sokikashima pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT kazukidoi pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT shintaronakayama pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT takanorisano pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT satoshiimai pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT tomihikoyasufuku pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT mototsugumuramaki pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma AT yujiyamada pathologicalcompleteresponseafternivolumabtherapyfollowingangiogenesisinhibitorsinapatientwithmetastaticrenalcellcarcinoma |